Healthcare Industry News: dilatation catheter
News Release - December 10, 2007
YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation CatheterSAN DIEGO, Dec. 10 (HSMN NewsFeed) -- YMed, Inc. announced today that it has successfully completed its first U.S. cases with its proprietary VascuTraK(TM) II PTA dilatation catheter. The VascuTraK(TM) II PTA Catheter is a unique 5F compatible, single operator rapid exchange system.
"The VascuTraK(TM) II catheter is an important advancement in technology for the treatment of patients with peripheral vascular disease (PVD), especially below the knee where amputation risks are the greatest," says Dr. Rajesh Dave, Chairman, Endovascular Medicine, Harrisburg Hospital, Harrisburg, PA. Dr. Dave performed the initial clinical cases with commercially available VascuTraK(TM) II catheters. He noted that in some lesion subsets, including calcified lesions involving the popliteal artery, the VascuTraK(TM) II catheter was sufficient to complete the intervention without adjunctive devices that may increase restenois or require further intervention.
YMed plans to initiate U.S. Sales with a broad range of VascuTraK(TM) II PTA dilatation catheters during Q1 2008, says Richard Cooper, Vice President Sales & Marketing, YMed, Inc. "The VascuTraK(TM) II is the first PTA dilatation catheter to combine the features of plaque modification and longer balloon lengths," Mr. Cooper added. Balloon diameters range from 2.0 mm to 4.0 mm in 0.5 mm increments with balloon lengths of 20 mm to 120 mm.
YMed, Inc. is a privately held Corporation established in 2004. The company was founded and is managed by a highly experienced, multinational team of medical, engineering and business professionals from within the cardio and peripheral vascular industry. This team develops, manufactures and markets innovative products for vascular intervention providing less invasive therapy for a broad range of circulatory diseases.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.